Marketing Authorization Holder Agreement Sample Contracts
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Marketing Authorization Holder AgreementMarketing Authorization Holder Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This is an agreement (the “Agreement”) made on and effective as of July 29, 2011 by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8560, Japan (hereinafter referred to as “MAH”).
Standard Contracts
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO MARKETING AUTHORIZATION HOLDER...Marketing Authorization Holder Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This Amendment (“Amendment 1”) is made this 1st day of September, 2013, by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8500. Japan (hereinafter referred to as “MAH”)
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO MARKETING AUTHORIZATION HOLDER...Marketing Authorization Holder Agreement • May 4th, 2016 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This Amendment (“Amendment”) is made this 1st day of April, 2016, by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as "MANUFACTURER", and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8560, Japan (hereinafter referred to as “MAH”).
AMENDMENT TO MARKETING AUTHORIZATION HOLDER AGREEMENT (“Amendment 3”)Marketing Authorization Holder Agreement • July 28th, 2017 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This Amendment (“Amendment 3”) is made this July 7th, 2017, by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Innovation Drive Milton Park, Abingdon, Oxfordshire OX14 4RZ United Kingdom (hereinafter referred to as "MANUFACTURER", and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at Art Village Osaki Central Tower 8F, 1-2-2 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan (hereinafter referred to as “MAH”).
